| 2026-03-10 |
Servier |
Day One Biopharmaceuticals |
~$2.5 billion |
Announced |
French pharma Servier acquires Day One, adding OJEMDA (tovorafenib) for pediatric low-grade glioma and a broader rare oncology pipeline. Expected to close Q2 2026. |
Link |
| 2026-02-23 |
Gilead Sciences |
Arcellx |
~$7.8 billion |
Announced |
Gilead acquires its existing CAR-T development partner to gain full control of anito-cel (BCMA-directed, multiple myeloma). $115/share cash + $5 CVR; 79% premium. FDA PDUFA date Dec. 23, 2026. Expected to close Q2 2026. Gilead's largest deal since Immunomedics ($21B, 2020). |
Link |
| 2026-02-09 |
Eli Lilly |
Orna Therapeutics |
~$2.4 billion |
Announced |
All-cash deal adds Orna's in vivo CAR-T platform using circular RNA and lipid nanoparticles. Lead program ORN-252 targets CD19 for B cell-driven autoimmune diseases. Early-stage but "clinical-trial ready" per Lilly. |
Link |
| 2026-01-20 |
Worldwide Clinical Trials |
Catalyst Clinical Research |
Not disclosed |
Announced |
CRO consolidation: Worldwide (Kohlberg-backed) acquires Catalyst, a specialist in early-phase oncology trials and FSP services. Catalyst Oncology and Catalyst Flex offerings to be integrated into Worldwide's portfolio. Expected to close Q1 2026. |
Link |
| 2026-01-13 |
Eli Lilly |
Ventyx Biosciences |
~$1.2 billion |
Announced |
Lilly acquires Ventyx and its IL-15 inhibitor for recurrent pericarditis and other cardiovascular/autoimmune conditions. |
Link |
| 2026-01-12 |
Hippocratic AI |
Grove AI |
Not disclosed |
Completed |
Strengthens Hippocratic AI's generative AI capabilities across pharma, biotech, and CRO settings; expands patient engagement and medical affairs AI agent offerings. |
Link |
| 2026-01-12 |
Eli Lilly (rumored) |
Abivax |
€15 billion (~$17.5B) |
Rumored |
French reports suggest Lilly is preparing offer for Abivax's obefazimod (ulcerative colitis/IBD). Abivax CEO has dismissed reports as "noise" with no formal discussions confirmed. |
Link |
| 2026-01-08 |
Verana Health + COTA |
Merger |
+$52M equity raise |
Completed |
Merger of two real-world data firms creates a combined platform with 95M+ patient records and 20,000+ clinicians. Strengthens oncology, ophthalmology, urology, and neurology RWD offerings for biopharma partners. |
Link |
| 2026-01-08 |
Merck (rumored) |
Revolution Medicines |
$28–32 billion |
Rumored |
MSD reportedly in talks to acquire Revolution Medicines for its late-stage oral RAS-targeted cancer therapies, including daraxonrasib. Would be among the largest biotech deals since Pfizer–Seagen. No formal agreement confirmed as of March 2026. |
Link |
| 2026-01-07 |
Merck & Co. |
Cidara Therapeutics |
~$9.2 billion |
Completed |
Merck completed acquisition of Cidara for its Phase 3 long-acting flu antiviral CD388 (now MK-1406). Deal closed via tender offer at $221.50/share. |
Link |
| 2026-01-06 |
Day One Biopharmaceuticals |
Mersana Therapeutics |
$25/share + CVR (up to $30.25) |
Completed |
Day One closed acquisition of Mersana, adding Emi-Le (emiltatug ledadotin), a B7-H4–directed ADC in early clinical trials for adenoid cystic carcinoma (ACC), a rare adult cancer with no approved therapies. |
Link |
| 2026-01-05 |
PharmaDrug |
Canurta Inc. (initial 19.9% interest) |
Not disclosed |
Completed |
Initial minority stake acquisition + debt restructuring (per company announcement). |
Link |
| 2026-01-05 |
W. L. Gore & Associates |
Medtech company behind foam-based LAAO system |
Not disclosed |
Announced |
Expansion of Gore's medical division via acquisition of an LAAO technology platform (per report). |
Link |
| 2026-01-05 |
Inspira |
Advanced liquid biopsy (cancer) (term sheet) |
~$12M earmarked (structure noted) |
Term sheet |
Signed a term sheet for acquisition; details include planned allocation of proceeds to fund ongoing ops (per release). |
Link |
| 2025-12-28 |
Johnson & Johnson |
Halda Therapeutics |
~$3.05 billion |
Completed |
Closed acquisition adding Halda's RIPTAC™ platform and clinical-stage prostate cancer program HLD-0915 (per J&J press release). |
Link |